Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Dechra Pharmaceutical reported a slight fall in profit even as the animal-drug developer outperformed in all its markets including in the USA where it delivered 'exceptional' organic growth.
For the financial year ended 30 June 2019, pretax profit fell 3.8% to £27.8m from a year earlier, while revenue increased by about 17% £481.8m with European pharmaceuticals revenue growth up about 17.5% and North America Pharmaceuticals revenue growth up about 19.8%.
The full year dividend was increased by 23.9% to 31.60 pence.
'Our strong growth, both organic and through acquisition, and our broadening product portfolio and increasing geographic reach positions us well for continued growth in this new financial year and beyond,' the company said. 'The outlook for the year ahead remains in line with management expectations.'